Windtree Therapeutics, Inc. – Common Stock (NASDAQ:WINT) reported quarterly losses of $(0.31) per share. This is a 42.59 percent increase over losses of $(0.54) per share from the same period last year.
Wedbush Initiates Coverage On Rani Therapeutics Hldgs with Outperform Rating, Announces Price Target of $28
Wedbush analyst Andreas Argyrides initiates coverage on Rani Therapeutics Hldgs (NASDAQ:RANI) with a Outperform rating and announces Price Target of $28.
